Purpose: To assess of the effect of local recurrence of uveal melanoma on metastasis using a multicenter international tumor registry.
Supplemental material is available at www.aaojournal.org.
Local tumor control is a primary goal in the treatment of cancer. 1 In 2002, the Collaborative Ocular Melanoma Study reported that local treatment failure occurred in 10.3% of Collaborative Ocular Melanoma Study patients who underwent iodine 125 plaque brachytherapy. 2 More recent studies, including a literature review of 49 articles, revealed local recurrence rates ranging from 0% to 55.6%. 3 Local orbital recurrence rates after enucleation are poorly documented, but are believed to be less than 1%. 4 These data are important, in that local tumor recurrence is a complication thought to be associated with an increased risk of uveal metastasis and thus decreased survival. 5e8 However, this current assumption that recurrence equals increased risk is supported by a relatively few, small singlecenter studies and 1 multicenter study; all are limited to 70 or fewer patients with local recurrence. 6e8 The Ophthalmic Oncology Task Force comprises members of the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control and includes eye cancer specialists from around the world. 9 For this study, 10 centers pooled their uveal melanoma patient data in an effort to study this disease. 10 We first used this database successfully to test the seventh edition AJCC uveal melanoma staging system. 11 In this study, we analyzed the data to define the relationships among local recurrence, extrascleral extension (EXE), and AJCC tumor size (T size). However, our primary goal was to investigate the largest collection of uveal melanomas with local recurrence and the impact of local recurrence on metastasis-free survival.
Methods
The Ophthalmic Oncology Task Force collaborated to develop an Internet-based retrospective registry to evaluate uveal melanoma outcomes. The methods of data collection and security have been described previously. 11 Each participating center obtained local ethics and institutional review board approval for participation and entry of patient data into the online database. This study conforms to the Declaration of Helsinki and the Health Insurance Portability and Accountability Act of 1996.
Patient Eligibility
Patient eligibility criteria included patients with primary melanoma of the iris, ciliary body, and choroid consecutively diagnosed and treated in a 10-year span from April 1, 2001 through April 30, 2011. Primary tumor treatment methods varied by center, with each type chosen at the discretion of the eye cancer specialists at each center. These were reported to include, but were not limited to, brachytherapy, enucleation or local resection (endoresection and lamellar eye wall resection), transpupillary thermotherapy with and without adjuvant radiation therapy, and stereotactic radiotherapy. However, no numerical treatment-related data were required for this database.
Detection of local tumor recurrence was determined by ultrasonography, comparative fundus photography, or inspection and palpation of the anophthalmic orbit (after enucleation). Local recurrence was determined by clinical and imaging studies used at each individual center. There were no exclusions to type of recurrence. Therefore, this study represents site-determined global clinical practice at 10 centers during this decade. Patients were excluded from analysis if they had metastasis (stage 4 disease) at initial staging.
Recorded outcome measures included local recurrence and metastasis. There were no limitations on the methods of screening for metastasis. However, these included abdominal ultrasound imaging, computed tomography, magnetic resonance imaging, or combined whole body positron emission tomography and computed tomography, as was the custom and practice at each center. Based on the current assumption that there is no current curative treatment for almost all patients with metastatic uveal melanoma and the recognized difficulties confirming the actual cause of death, this study defined metastasis to be synonymous with metastatic death.
Statistical Analysis
Categorical variables were described using frequencies and proportions. Time to local recurrence was measured from the date of initial staging. Patients who were alive and free of local recurrence at last follow-up were censored. One hundred thirty patients (4%) died without local recurrence. Because the number of competing risk events (death without local recurrence) was small relative to the size of the data set, these patients were censored at their date of death. Standard methods were used for analysis, rather than implementing competing risks methodology. Kaplan-Meier plots, a standard Cox proportional hazards model, and the log-rank test for trend were implemented to test for a trend relationship between time to local recurrence and T size (based on the AJCC 7th edition criteria). 12 The standard log-rank test was implemented to test for a relationship between time to local recurrence and EXE.
Time to metastasis was measured from the date of staging until the date of metastasis; patients who were alive and free of metastasis at last follow-up were censored. Twenty-five patients died without metastasis. Because the number of patients in this latter category was small relative to the size of the data set, these patients were censored at their date of death rather than treating their death as a competing risk event. A Kaplan-Meier plot and the log-rank test were implemented to test for a relationship between time to metastasis and local recurrence at last follow-up.
The effect of a local recurrence on the risk of metastasis after staging also was investigated using Cox models, with local recurrence treated as a time-varying covariate. In the univariate model, other factors were not taken into account. An unadjusted (univariate) model and a model adjusted for stage, T-size category, and ciliary body involvement or EXE grouping were implemented. Kaplan-Meier plots, a standard Cox proportional hazards model, and the log-rank test were implemented to test for a relationship between time to local recurrence and EXE.
In the analysis of time to metastasis after a local recurrence, only patients who experienced a local recurrence were included. Patients who experienced metastasis before a local recurrence or on the same date as local recurrence were included with their time to metastasis set to 0.00001 years. Those who had no metastasis and no follow-up after their local recurrence were excluded. The related estimates are generalizable to all patients who had a local recurrence. The Kaplan-Meier curves estimate the probability of being free of metastasis after a local recurrence. The 95% confidence limits for this sub-analysis were calculated using the method of Greenwood 13 and the complementary log-log transformation.
The survival package in R software (R Core Team, Vienna, Austria) version 2.15.1 was used to generate Kaplan-Meier plots; SAS TS level 1M1 version 9.3 software (SAS Inc, Cary, NC) was used to perform all other statistical analyses. Statistical significance was set to 0.05. 
Results

Participating Centers
Ten ophthalmic oncology centers from 8 countries (Argentina, Canada, Japan, Russia, Spain, Sweden, The Netherlands, and the United States) in 4 continents (North and South America, Europe, and Asia) participated in this study.
Patients
Three thousand eight hundred nine patients with uveal melanoma were entered into the online database and staged according to the 7th edition of the AJCC system. Of these, 3377 (89%) records were complete. One hundred eighty-one patient entries were eliminated because of lack of follow-up and 67 were eliminated because of initial presentation with stage 4 disease (metastasis). One hundred eighty-four were removed because of missing or inconsistent key variables. This included 118 with unknown metastasis status, 35 with unknown EXE status, 11 with unknown ciliary body involvement status, and 128 with incomplete or inconsistent data that prevented being assigned a T-size category or prognostic stage. Some patient entries were eliminated for more than 1 of the above reasons. Primary ciliary body and choroidal melanoma was the diagnosis for 3217 patients, and 160 patients had primary iris melanoma. The median follow-up from date of initial diagnosis and staging for the 3217 patients was 3.7 years (95% confidence interval [CI], 3.5e3.8; range, 0.1e12.6 years; Table 1 ).
Ciliary Body and Choroidal Melanoma Recurrence
One hundred fifty-two patients (4.7%; n ¼ 152/3217) with ciliary body and choroidal melanoma experienced local recurrence by their last follow-up. Kaplan-Meier point estimates for remaining free of local recurrence were 99% (95% CI, 99%e99%) at 1 year, 93% (95% CI, 92%e94%) at 5 years, and 89% (95% CI, 86%e91%) at 10 years after treatment.
Kaplan-Meier estimates of time to local treatment failure are shown graphically in Figure 1A and numerically in Figure 1B . Five years after initial tumor staging, an estimated 7.3% of eyes (95% CI, 6.1%e8.7%) exhibited treatment failure, and an estimated 11% of eyes exhibited treatment failure at 10 years (95% CI, 8.9%e 13.7%). Local recurrence was detected as early as 1 month and as late as 9.8 years after initial tumor staging (Fig 1B) .
Local Recurrence and Metastasis
Kaplan-Meier point estimates at 5 and 10 years after initial tumor staging show that there is a statistically significant difference in the metastasis-free survival for the recurrence and recurrence-free groups (P < 0.001). Forty-three of the 152 patients (28.3%) with local recurrence demonstrated metastasis, compared with 287 (9.4%) of those who were free of recurrence. For the recurrencefree group, the 5-and 10-year metastasis-free estimates were 87% (95% CI, 86%e89%) and 82% (95% CI, 79%e84%), whereas the recurrence group estimates were 71% (95% CI, 62%e78%) and 62% (95% CI, 49%e72%), respectively (Fig 2) . In a univariate Cox model, local recurrence increased the risk of metastasis by a hazard ratio (HR) of 6.28 (95% CI, 4.42e8.92). Thus, failure of local control was shown to be associated with a statistically significant (P < 0.001) increase in metastatic disease. Multivariate analysis adjusting for AJCC stage, T-size category, and presence of ciliary body involvement or EXE demonstrated that local recurrence was still associated with an increased risk of metastasis (HR, 6.46; 95% CI, 4.52e9.24; P < 0.001).
Local Recurrence According to American Joint Committee on Cancer T-Size Category
According to T-size category and using the entire 3217-patient cohort, 4.6% of patients in size category T1 (51/1115), 5.7% of patients in size category T2 (64/1128), 4.3% of patients in size category T3 (34/789), and 1.6% of patients in size category T4 (3/185) had local recurrence. The evidence failed to show a trend relationship between T-size category and local recurrence (P ¼ 0.63, log-rank test for trend; Kaplan-Meier estimates did not show a trend). No HRs from a Cox proportional hazards model were statistically significant (all P ¼ 0.12 and higher).
Extrascleral Extension and Local Recurrence
Of the 152 patients with local recurrence, 7 patients had EXE. Using the entire cohort of 3217, 12.5% (7/56) with EXE demonstrated local recurrence as compared with 4.6% (145/3161) without EXE who demonstrated local recurrence. The HR from a Cox proportional hazards model indicated that the presence of EXE was associated with a higher risk of local recurrence (HR, 3.2; 95% CI, 1.5e6.7; P ¼ 0.003).
Time from Local Recurrence to Metastasis
Only patients who experienced a local recurrence (n ¼ 152) were included in the analysis of time from local recurrence to metastasis. Of these, 43 patients (28% [43/152]) with local recurrence demonstrated metastasis. Six (3.9%) had already experienced metastasis before local recurrence, 9 (5.9%) had metastasis and local recurrence detected on the same date, 8 (5.3%) had no followup after their local recurrence, and 28 (18.4%) experienced metastasis after local recurrence. One hundred one patients (66.4%) had additional follow-up after their local recurrence date and did not demonstrate metastasis (during that time).
After excluding 8 patients because of a lack of follow-up after local recurrence, a cohort of 144 was used to evaluate time to metastasis, with a median follow-up after local recurrence of 2.3 years (95% CI, 1.8e3.0 years). Forty-three of the 144 patients (29.9%) who had a local recurrence also had a metastasis either before, at the same time as, or after local recurrence; the remaining 70.1% of the sample remained free of metastasis by their last follow-up date. The median time to metastasis was 6.8 years; however, in Figure 3 , note this estimate was based on a small number remaining at risk for local recurrence with a large 95% CI (95% CI, 6.2eupper limit cannot be calculated). The longest interval from local recurrence to detection of metastasis was 9.8 years. Two (1.4%) patients died without metastasis.
Local Recurrence of Iris Melanoma
Of the 160 patients with iris melanoma, 5 (3.1%) demonstrated local recurrence by their last follow-up. Of these 5 patients, 2 were in T-size category T1, and 3 were T2. One experienced metastasis 2 years after local recurrence, 3 had follow-up after their local recurrence date (6 months, 6 months, and 3 years) and did not experience metastasis during that time, and 1 had no follow-up after local recurrence (and no metastasis). Kaplan-Meier point estimates (n ¼ 160) for remaining free of local recurrence were 99% (95% CI, 95%e100%) at 1 year, 95% (95% CI, 88%e98%) at 5 years, and 93% (95% CI, 82%e97%) at 10 years. This subset was too small for further statistical analysis.
Discussion
Our study revealed that local tumor recurrence significantly increases the risk of metastatic melanoma (P < 0.001; HR, 6.28). This is the highest HR reported to date. Previous single-center studies evaluating posttreatment local recurrence also have found an increased risk of metastasis (Table 1) . For example, Gragoudas et al 7 found a relative risk of 4.1 for those with local recurrence (n ¼ 62) after proton beam irradiation. Vrabec et al 8 reported on cobalt 60 plaque brachytherapy (n ¼ 70) and found a statistically significant decrease in the estimated 5-year survival between their local recurrence-free (87%) and recurrence (58%) groups. In another single-center study, Caujolle et al 6 Figure 2 . Kaplan-Meier metastasis-free probability for 3217 ciliary body and choroidal melanoma patients with versus without local recurrence (LR) (P < 0.001). (n ¼ 61) noted that survival rates in uveal melanoma patients after proton beam therapy decreased from 83.6% (in those without recurrence) to 55% in those with local recurrence at 10 years. When compared with our relatively large (n ¼ 152) multicenter study, we found that patients with local recurrence fared slightly better, with 71% (5 years) and 62% (10 years) demonstrating metastasis-free survival.
Unlike the aforementioned studies, we analyzed local tumor recurrence following the standard of care in multiple international eye cancer centers using their bestrecommended treatment strategies. That is, the study cohort included patients treated with varying types of primary tumor treatment and was not limited to a single treatment method. Thus, local recurrence rates best reflect the standard of care during that decade. This study provides evidence that local recurrence significantly increases the risk of metastasis despite the type of primary tumor treatment.
Local radiation failure has been attributed to radiation resistance, misplacement of radioactive plaque, insufficient radiotherapeutic margins, and eye movement (primarily during charged-particle beam therapy). 5, 14 Therefore, our findings support the use of methods to improve local control (e.g., intraoperative ultrasound to evaluate plaque placement, slotted plaque radiotherapy, 2e3-mm radiotherapeutic margins, adequate tumor dose and eye fixation during external beam techniques).
15e20 Transpupillary thermotherapy and resection can be augmented by adjuvant radiation treatment.
21e23 Clearly, our findings suggest that all uveal melanoma patients be counseled of greater risks for metastatic disease should their primary tumor treatment fail.
This study does not examine the exact mechanism of how local recurrence increased the risk of metastasis. In addition to therapeutic failure, theories include that recurrent tumors may have physiologic, genetic, or anatomic characteristics that made them more malignant or early to metastasize. 11,24e28 It also has been proposed that these biomarkers may contribute both to outcomes of local recurrence and to metastasis. However, this study was not designed to analyze these complex genetic or biological predisposing factors. Rather, it was designed to evaluate the relationship between local recurrence and the incidence of metastatic disease. Certainly, those determining the prognostic efficacy of such tumor-specific biomarkers should consider failure of local control in their calculations.
In conclusion, the Ophthalmic Oncology Task Force's uveal melanoma registry clearly demonstrates that multicenter, international data sharing can be used to examine statistically important clinical questions such as the impact of failure of local control on metastatic risk. This study revealed that local recurrence of uveal melanoma is associated with a statistically significant increase in metastasis and that this subgroup of high-risk patients deserves increased surveillance for metastatic disease.
